NEW YORK – Findings from a randomized, Phase II clinical trial suggest adding bevacizumab (Genentech's Avastin) to erlotinib (Tarceva from Genentech/Astellas) treatment does not extend progression-free survival for patients with EGFR-mutated, non-small cell lung cancer (NSCLC) compared to erlotinib alone.

"Compared with erlotinib, the combination did not result in a significant difference in PFS," first and corresponding author Thomas Stinchcombe, a medical oncologist and investigator at the Duke Cancer Institute, and his colleagues wrote.